Does Bioventus (BVS) have what it takes to be a top stock pick for momentum investors? Let's find ou

The mean of analysts' price targets for Bioventus (BVS) points to a 28.8% upside in the stock. While

Bioventus Inc. develops medical devices and biologics for orthopedic recovery and pain relief. I pre

Bioventus (BVS) was a big mover last session on higher-than-average trading volume. The latest trend

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or ob

Gainers Seer (NASDAQ:SEER) stock moved upwards by 33.3% to $2.16 during Thursday's after-market

FA, BVS and OOMA emerged as July breakout stock picks after meeting momentum and price-based screens

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

Bioventus NASDAQ: BVS executives outlined the company's portfolio strategy, growth priorities and ca

Bioventus Inc. (BVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcr

The heavy selling pressure might have exhausted for Bioventus (BVS) as it is technically in oversold

DURHAM, N. C. , June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in i

Bioventus (BVS) appears to have found support after losing some value lately, as indicated by the fo

On April 16, 2026, the U.S. Food and Drug Administration ("FDA") issued a final order reclas

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

Here is how Bioventus (BVS) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their

Consumer confidence is breaking down in a way investors have not seen in years. The University of Mi

The consensus price target hints at a 39% upside potential for Bioventus (BVS). While empirical rese

Bioventus Inc. (BVS) Q1 2026 Earnings Call Transcript

Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Est

Bioventus (NASDAQ:BVS) raises FY2026 Adj EPS guidance from $0.73-$0.77 to $0.75-$0.79 vs $0.75 analy

Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.15 per share which beat the analyst consens

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for it

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

Gainers Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) shares jumped 153% to $3.24 after the co

  On Thursday, 588 stocks hit new 52-week lows.